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http://dx.doi.org/10The DDX41 gene, encoding a DEAD-box type ATP-dependent RNA helicase, is rarely but
reproducibly mutated in myeloid diseases. The acquired mutation in DDX41 is highly concen-
trated at c.G1574A (p.R525H) in the conserved motif VI located at the C-terminus of the heli-
case core domain where ATP interacts and is hydrolyzed. Therefore, it is likely that the
p.R525H mutation perturbs ATPase activity in a dominant-negative manner. In this study,
we screened for the DDX41 mutation of CD34-positive tumor cells based on mRNA
sequencing and identified the p.R525H mutation in three cases among 23 patients. Intrigu-
ingly, these patients commonly exhibited acute myeloid leukemia (AML) with peripheral
blood cytopenias and low blast counts, suggesting that the mutation inhibits the growth and
differentiation of hematopoietic cells. Data from cord blood cells and leukemia cell lines sug-
gest a role for DDX41 in preribosomal RNA processing, in which the expression of the
p.R525H mutant causes a certain ribosomopathy phenotype in hematopoietic cells by sup-
pressing MDM2-mediated RB degradation, thus triggering the inhibition of E2F activity.
This study uncovered a pathogenic role of p.R525H DDX41 in the slow growth rate of tumor
cells. Age-dependent epigenetic alterations or other somatic changes might collaborate with
the mutation to cause AML. Copyright  2016 ISEH - International Society for Experi-
mental Hematology. Published by Elsevier Inc.Current comprehensive sequencing approaches led to
the identification of rare but reproducible somatic gene
mutations in myeloid malignancies. Among them, there is
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.1016/j.exphem.2016.04.017DEAD-box type ATP-dependent RNA helicase. The so-
matic mutation in DDX41 is highly concentrated at
c.G1574A (p.R525H) in the conserved motif VI, located
at the C-terminus of the RecA-like helicase core domain
where ATP interacts and is hydrolyzed. Therefore, it is
likely that the p.R525H mutation in the DDX41 protein per-
turbs ATPase activity in a dominant-negative manner. In
addition, germline mutations in DDX41 were recently iso-
lated in a subset of familial acute myeloid leukemia
(AML)/myelodysplastic syndrome (MDS) pedigrees [1,2].
Because the roles of these somatic and germline mutations
in the pathogenesis of myeloid diseases are not completely
understood, the researchers who first described these muta-
tions advocate a role for DDX41 in mRNA splicing viamatology. Published by Elsevier Inc.
746 M. Kadono et al./ Experimental Hematology 2016;44:745–754interaction with the U2 and U5 complexes [1]. However,
unlike canonical spliceosomal mutations, the DDX41 muta-
tion causes, not only MDS, but also primary AML.
In this study, we propose a role for DDX41 as a precur-
sor ribosome RNA (pre-rRNA) processing factor in which
the p.R525H mutation affects ribosome biogenesis. We
found that ribosome biogenesis was affected widely when
cord blood–derived CD34-positive cells were transfected
with DDX41 p.R525H, thus compromising cell cycle pro-
gression through impaired E2F function. Because molecu-
lar mechanisms for the development of AML with
cytopenias have not been elucidated, we propose here that
the DDX41 p.R525H mutation in hematopoietic stem/pro-
genitor cells is involved in the pathogenesis of a certain
subset of such AML cases.
Methods
Patient samples and cell fractionation
Bone marrow aspirates or peripheral blood specimens were
collected from 23 patients with AML who participated in the study
according to the protocol approved by the ethics committee on hu-
man genome research at Hiroshima University and Kumamoto
University. The protocol was based on an opt-out or on written
informed consent obtained by the patients. The protocol included
the use of pooled samples at initial diagnosis. Total RNA was ex-
tracted from CD34-positive cell fractions isolated by magnetic
activated cell sorting. Where possible, CD3-positive and CD34-
negative/CD3-negative fractions were isolated.
mRNA sequencing
In this study, gene mutations were screened upon mRNA
sequencing. The libraries for mRNA sequencing were prepared
according to the SureSelect library preparation kit (Agilent Tech-
nologies, Santa Clara, CA) and subjected to massively parallel
sequencing with a GAIIX or Hiseq2500 sequencer (Illumina,
San Diego, CA) using a single-end 36-bp or 50-bp sequencing
length protocol. Sequenced tags were aligned to the human refer-
ence genome (build hg19) using ELAND (Illumina), and gene
expression was normalized to the amount of reads per kilobase
of exon per million mapped (rpkm).
Antibodies
The following antibodies were used in this study: anti-DDX41
(ab182007; Abcam, Cambridge, UK), anti-Actin (MAB1501; Merck
Millipore, Darmstadt, Germany), anti-FLAG M2 (F3165; Sigma-
Aldrich, St. Louis, MO), anti-Myc-tag (2272; Cell Signaling Tech-
nology, Danvers, MA), anti-Nucleolin (M019-3S; MBL, Nagoya,
Japan), anti-RPL5 (ab86863; Abcam), anti-RPL11 (ab79352;
Abcam), anti-RB (9313; Cell Signaling Technology), anti-phospho-
RB (9301; Cell Signaling Technology), anti-MDM2 (ab3110; Ab-
cam), and anti–multi-ubiquitin (D058-3; MBL).
Vector construction
DDX41 and other cDNAs used in this study were obtained by po-
lymerase chain reaction (PCR) amplification from human cord
blood–derived total RNA and cloned into pMYs-IG retrovirus vec-
tor [3]. Point mutations and truncations were generated using a
site-directed mutagenesis approach.Cell culture and plasmid transfection
Cord blood–derived CD34-positive cells were purchased from the
RIKEN Cell Bank (Ibaraki, Japan). The cells were cultured on
Tst4/min feeder cells (kindly provided by Dr. H. Kawamoto at
Kyoto University) in Dulbecco’s modified Eagle medium supple-
mented with 20% fetal bovine serum (FBS) in the presence of hu-
man stem cell factor (SCF), FMS-related tyrosine kinase 3 ligand
(FLT3-L), and thrombopoietin (TPO; 100 ng/mL each). THP-1
and K562 cells were cultured in RPMI1640 medium containing
10% FBS. For enforced gene expression, pMYs-IG retroviral vec-
tor and PLAT-E or PLAT-F packaging cells were used.
Immunofluorescence analysis
Murine lung fibroblasts grown on coverslips were infected with a
retrovirus and cultured for 2 days. THP-1 cells were first trans-
duced with retrovirus and then attached to a glass slide using a cy-
tospin apparatus. The cells were fixed with 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100, and blocked with 1%
bovine serum albumin (BSA), followed by staining with primary
antibodies. After staining with Cy3-or Alexa Fluor 488-labeled
secondary antibodies and Hoechst 33342, fluorescent signals
were observed, and the images were taken using a confocal laser
scanning microscope (LSM 5; Carl Zeiss Microscopy, Jena,
Germany).
Immunoblot and immunoprecipitation analysis
Cells (1  106) were extracted with NP40 lysis buffer (50 mM
Tris-HCl pH 8.0, 150 mM NaCl, and 1.0% NP40) containing pro-
teinase and phosphatase inhibitor cocktails (Complete and Phos-
STOP; Roche Life Sciences, Indianapolis, IN). For
immunoprecipitation analysis, protein G-coated magnet beads
(20 mL in each experiment) were conjugated with an antibody
(4 mg) and mixed with cell extracts overnight at 4C. The beads
were washed five times with NP40 lysis buffer and then resus-
pended with 50 mL of sample buffer (NP40 lysis buffer containing
1% sodium dodecyl sulfate, 0.5% b-mercaptoethanol, and 12.5%
glycerol), followed by denaturation and elution by heating at
95C for 2 minutes. The samples were loaded and electrophoresed
on 8.5%, 12.5%, or 15% polyacrylamide gels according to the mo-
lecular weight of the protein of interest.
Northern blotting analysis
Northern blotting analysis was performed based on a non-RI pro-
tocol according to the manufacturer’s instructions (DIG Northern
Starter Kit; Roche Life Sciences). Briefly, 1.5 mg of total RNAwas
denatured and fractionated using a denaturing gel (2% formalde-
hyde/1.2% agarose), followed by transfer to a nylon membrane.
The membranes were hybridized with digoxigenin-labeled RNA
probes, and the signals were detected using alkaline-phospha-
tase–labeled antidigoxigenin antibody and a chemiluminescent
substrate. RNA probes in this assay were prepared by PCR ampli-
fication of internal transcribed spacer 1 (ITS1) and ITS2 regions
(for ITS1, forward primer: 50-acggagcccggagggcgaggcccgc-30,
reverse primer: 50-cgtctccctcccgagttctcggctc-30; and for ITS2, for-
ward primer: 50- ctaagcgcagacccggcggcgtccg-30, reverse primer:
50- acgggaactcggcccgagccggctc-30), followed by in vitro transcrip-
tion using DIG-11-UTP for probe labeling. The ITS1 probe was
used for the identification of 47S, 45S, 30S, and 21S pre-rRNA,
whereas the ITS2 probe was used for 47S, 45S, 32S, and 12S
detection (Supplementary Figures E1A and E1B, online only,
747M. Kadono et al./ Experimental Hematology 2016;44:745–754available at www.exphem.org). Schematic pre-rRNA–processing
pathways are shown in Supplementary Figure E1B.
ATPase assay
The assay reaction (10 mL) contained the following components:
50 mM Tris-HCl, pH 7.4, 20 mM MgCl2, 50 mM KCl, 3.33 pM
[a-32P]ATP, and 0.2 mg of helicase domain of DDX41 purified
by an in vitro translation system (Trans-direct insect cell; Shi-
madzu, Kyoto, Japan). BSA was used as a negative control. Sam-
ples were incubated for 15 or 30 minutes at 37C, and the reaction
was stopped by adding 1 mL of 0.5M EDTA, pH 8.0. The reaction
mixture (1 mL) was then spotted on a cellulose PEI-F plate (Avan-
tor Performance Materials, Center Valley, PA) and developed by
ascending chromatography in 0.75 M LiCl/1 M formic acid solu-
tion for 1 hour. The plate was air dried and the ATP/ADP signals
were detected by autoradiography.B
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10 81/M 47,XY,+der(1;19)(q10;p10) (3/20cells), 46,XY (17/20cells) 0.
17 64/M 46,XY 3.
2995      
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Figure 1. Identification of the somatic DDX41 p.R525H mutation in AML patie
harboring the p.R525H DDX41 mutation. The images were taken at 400 magnifi
bottom. (B) Confirmation of somatic DDX41 p.R525H mutation by Sanger re
negative, and CD3-positive cells from patient UPN17 are shown. Arrow indicateMouse bone marrow transplantation (BMT)
C57BL/6 (Ly5.1) mice (Sankyo Labo Service Corporation, Tokyo,
Japan) and C57BL/6 (Ly5.2) mice (Charles River Laboratories
Japan, Kanagawa, Japan) were used for BMT experiments. A total
of 100,000 cells (Ly5.1) transduced with a DDX41/GFP expression
vector was transplanted into sublethally irradiated recipient mice
(Ly5.2), and peripheral white blood cell (WBC) numbers and
green fluorescent protein signals were measured 2–3 months later.
Results
Identification of the DDX41 p.R525H mutation in three
AML patients
We screened for the DDX41 mutation of CD34-positive tu-
mor cells based on mRNA sequencing and identified aC 
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nts exhibiting cytopenias. (A) Bone marrow blasts of three AML patients
cation. Clinical manifestations of the patients are shown in the table at the
sequencing. Representative data of CD34-positive, CD34-negative/CD3-
s the p.R525 position.
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(chr5: 176,939,370 on build GRCh37/hg19) in three cases
among 23 patients (Fig. 1A). Although we did not perform
comprehensive sequencing of paired germline DNA, we
confirmed the mutation as somatic by the direct genome
sequencing of CD3-positive cells (Fig. 1B). Intriguingly,
these patients, in addition to a patient with the same muta-
tion enlisted in the Cancer Genome Atlas [4], exhibited
AML with peripheral and bone marrow cytopenias and
low blast counts (Fig. 1A), although the precise cellularity
of the bone marrow was undetermined because a bone
marrow biopsy was not performed. In addition, a recent
study described a germline p.R525H mutation associated
with bone marrow hypocellularity and low WBC count in
a primary AML patient [2]. According to our transcriptome
data on patients’ CD34-positive cells, almost one half of the
sequenced tags at c.G1574 were considered mutated in each
patient (18 of 37, 19 of 32, and 23 of 47 reads were called
‘‘A’’). Therefore, almost all CD34-positive cells in theseDDX41 (p.R525H)-Myc
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Figure 2. Nuclear localization of DDX41. (A) Localization of Myc-tagged hum
DDX41 protein with or without a p.R525H substitution was expressed together
FLAG mouse antibody were used as primary antibodies; a Cy3-labeled antirabb
as secondary antibodies. Nuclei were stained with Hoechst 33342. Scale bars: 20
to a glass slide using a cytospin apparatus, were stained with an anti-DDX41 and
Rabbit antibody and an Alexa Fluor 488-labeled anti-Mouse antibody, respective
Scale bar, 20 mm. (C) Schematic illustration of the DDX41 protein structure. The
methionine, and the motif VI in the helicase domain are shown in red.patients may harbor a heterozygous DDX41 p.R525H muta-
tion, although deeper sequencing analysis is required to
assess the precise variant allele frequencies. Conversely,
CD34-negative cells carrying the mutation were fewer
compared with CD34-positive cells, and CD3-positive cells
carrying the mutation were almost absent, as estimated by
direct genomic DNA sequencing (Fig. 1B). These data sug-
gest a somatic nature of the mutation in the patient and a
block in the differentiation of CD34-positive DDX41
mutant cells into negative cells.
Nuclear localization of the DDX41 protein
We next clarified the localization of the DDX41 protein. In
this experiment, FLAG-tagged STING, a protein that had
been reported to interact with DDX41 at the endoplasmic
reticulum [5,6], was coexpressed with Myc-tagged
DDX41 in fibroblasts. Ectopically expressed DDX41 was
mostly nuclear regardless of the p.R525H mutation and
minimally colocalized with FLAG-STING in a steady stateBc
Hoechst33342
An-DDX41 
(Cy3)
An-
Nucleolin
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Hoechst33342
Merged
YVHRIGRTGRSGN
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Mof VI
C
622
↓
kDa 
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an DDX41 protein in murine fibroblasts by immunofluorescent analysis.
with a FLAG-tagged STING. An anti-Myc rabbit antibody and an anti-
it antibody and Alexa Fluor 488-labeled antimouse antibodies were used
mm. (B) Endogenous DDX41 expression in THP-1 cells. The cells, attached
an anti-Nucleolin antibody, followed by staining with a Cy3-labeled anti-
ly. The images were taken using a LSM-5 PASCAL confocal microscopy.
helicase core domain is shown in light blue. A predicted NLS, the second
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DDX41 protein was also mostly nuclear (Fig. 2B). In the
nucleus, DDX41 protein localized both in the nucleoplasm
and in the nucleolus (stained with nucleolin), suggesting
that DDX41 plays a role in the nucleoplasm as well as in
the nucleolus. Although previous studies described
DDX41 as a cytosolic DNA sensor that recognizes nucleic
acids of pathogens [6], our study did not suggest this func-
tion based on the protein localization. However, we identi-
fied a 52-kDa DDX41 short isoform translated from the
second methionine in addition to the full-length 70-kDa
DDX41 (Fig. 2C; Supplementary Figures E2A and E2B,
online only, available at www.exphem.org). This short
form, which lacks a putative nuclear localizing signal
(NLS) and is detected both in the cytoplasm and in the nu-
cleus (Fig. 2C; Supplementary Figure E2C, online only,
available at www.exphem.org), might function as a sensor
of pathogenic nucleic acids.
Growth inhibition of p.R525H DDX41-expressing cells
due to impaired pre-rRNA processing
To investigate the molecular functions of DDX41 in he-
matopoietic cells, cord blood–derived human CD34-
positive cells were transduced with wild-type (WT) or
p.R525H DDX41 using a retroviral system [3], followed
by cultivation in the presence of 100 ng/mL SCF, TPO,
and FLT3-L. After a 30-day culture, p.R525H cells showed
decreased proliferation compared with WT cells (Fig. 3A),
and this was accompanied by the suppression of mRNAs
encoding ribosomal proteins (Supplementary Figure E3A,
online only, available at www.exphem.org). A gene set
enrichment analysis (GSEA) [7] showed that the gene
expression pattern of p.R525H cells was negatively corre-
lated with ribosomal gene sets and with myc target genes
(Supplementary Figure E3B, online only, available at
www.exphem.org). GSEA further indicated an enrichment
of the genes upregulated in the absence of RPS14 inA
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Figure 3. Cell growth inhibition by DDX41 p.R525H mutation that causes imp
cells transfected with a DDX41-expressing vector or an empty vector in the presen
number of cells at 30 days and at the beginning of the assay. The right graph show
assay using a helicase domain of the DDX41 (WT and p.R525H mutant) protein a
for the indicated minutes, and the mixtures were subjected to thin-layer chromap.R525H cells (Supplementary Figure E3B). These data
suggest that a certain ribosomopathy [8] may occur in the
mutant DDX41-expressing cells.
These findings and a highly conserved DEAD-box type
RNA helicase domain of DDX41 led us to speculate that
the DDX41 protein might be involved in pre-rRNA process-
ing. A recent study also supports this speculation [9]. As
expected from the position of the somatic mutation
(p.R525), which is within the helicase core where the
ATP binds and is hydrolyzed (Fig. 2C) [10], the mutant
helicase domain displayed a lower ATPase activity
(Fig. 3B). In addition, northern blot analysis probing
ITS1 and ITS2 of pre-rRNA showed increased signals of
47S and 41S pre-rRNAs (Fig. 3C). The 30S signal was
slightly upregulated, whereas the 21S signal was decreased
in THP-1 cells expressing p.R525H DDX41. Instead, the
32S signal was increased both in WT and p.R525H cells.
Furthermore, semiquantitative real-time PCR experiments
showed relatively higher amounts of pre-rRNA containing
50 external transcribed spacer (ETS) or ITS2 than that con-
taining ITS1 in p.R525H cord blood cells (Fig. 3D).
Although the precise phase at which DDX41 takes part in
pre-rRNA processing has not been elucidated, this series
of experiments suggests a role for DDX41 in the trimming
of 50 ETS and/or ITS2.
Activation of RB pathway occurring in p.R525H
DDX41-expressing cells
As mentioned previously, p.R525H DDX41 cord blood
cells were fewer than WT cells after the culture
(Fig. 3A), but the induction of apoptosis was unlikely
because cell viability was maintained at almost 100%
throughout the culture (data not shown). Recent studies
on ribosomopathies revealed an activation of the MDM2-
p53 pathway in the pathogenesis of the diseases [11,12].
It is now widely recognized that RPL5 and RPL11 not
incorporated into the 60S ribosome bind preferentially to15min. 30min.
ATP
WT
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B
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Figure 3. (continued) (C) Detection of pre-rRNA intermediates expressed in THP-1 cells by northern blotting analysis. DIG-labeled RNA probes for ITS1
and ITS2 regions were used for the detection (Supplementary Figure E1A). The right panels indicate lane profile plots generated from the northern blots (left
panels) using ImageJ software and quantitative values of each pre-rRNA band relative to the empty vector control. (D) Relative amounts of pre-rRNA spacers
as assessed by quantitative PCR analysis. Empty vector or DDX41 (p.R525H and WT)-transfected cord blood cells were subjected to quantitative PCR ex-
periments. The regions amplified by PCR are shown in Supplementary Figure E1A.
750 M. Kadono et al./ Experimental Hematology 2016;44:745–754MDM2, so inhibition of p53 by MDM2 is compromised,
causing a stimulation of the p53 pathway [13,14]. We
initially assumed that the same defect might be involved
in the growth impairment of p.R525H DDX41 cells. Never-
theless, GSEA did not indicate p53 activation in the cells,
probably because we cultured cord blood cells with a com-
bination of cytokines (SCF, FLT3-L, and TPO). This com-
bination is expected to expand hematopoietic stem/
progenitor cells with less differentiation. Data from tran-
scriptome analysis suggested no erythroid differentiationin this culture condition, in which globin genes were almost
not expressed at all. Given that ribosomal defect-mediated
activation of p53 pathway occurs preferentially in the
erythroid lineage in ribosomopathies, our culture conditions
might not have been optimal to observe p53 activation.
Instead, GSEA revealed a negative enrichment of cell
cycle–promoting genes regulated by the RB-E2F axis in
p.R525H DDX41 cord blood cells (Fig. 4A). Cell cycle in-
hibition through the suppression of E2F activity was also
detected in patient-derived samples (Fig. 4B). In our study,
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Figure 4. Ribosomal stress that results in the activation of RB pathway occurring in p.R525H-expressing cells. (A) Negative enrichment of cell
cycle–promoting genes regulated by the RB-E2F axis in DDX41 p.R525H cord blood cells. GSEA analyses were performed using mRNA-sequencing
data in which the plots of ‘‘Chang Cycling Genes,’’ ‘‘Hallmark E2F Targets,’’ and ‘‘Eguchi Cell Cycle RB1 Targets’’ are shown as representatives. Normalized
enrichment score, nominal p value, and false discovery rate (FDR) q value are indicated at the bottom. (B) Negative enrichment of cell cycle–promoting
genes regulated by the RB-E2F axis in CD34-positive tumor cells obtained from patients (three patients with the p.R525H mutation were compared with
20 patients without the mutation). GSEA analyses were performed as in (A).
751M. Kadono et al./ Experimental Hematology 2016;44:745–754we found increased RPL5 and RPL11 bound to MDM2 in
p.R525H DDX41 cells (Fig. 4C). Because the total amount
of these ribosomal proteins was apparently not altered by
the enforced expression of p.R525H DDX41, the mutant
DDX41 might increase free ribosomal proteins that are
not incorporated into the 60S ribosome, and these proteins
may eventually form a complex with MDM2. Moreover,
the RB protein was increased in p.R525H DDX41 cells,
in part due to the inhibition of MDM2-mediated poly-
ubiquitination (Fig. 4D). The RB protein was active in
p.R525H DDX41 cells because it was dephosphorylated,
although the mechanism of the dephosphorylation is
currently unclear. Furthermore, impaired growth was
observed in p.R525H DDX41 THP-1 cells lacking WT
p53 (Supplementary Figure E4A, online only, available
at www.exphem.org) [15], implying a p53-independent
but RB-dependent cell cycle inhibition by the mutant
DDX41.Discussion
In this study, we performed mRNA sequencing on 23 pa-
tients and identified the DDX41 p.R525H mutation in threeAML patients. The rate of somatic DDX41 mutation was
high compared with previous studies because of our limited
number of patients or because of the use of CD34-positive
cells in our study. In most previous studies, whole genome
or exome sequencing was performed using total bone
marrow or peripheral blood specimens. Given that tumor
cells harboring the DDX41 mutation rarely divide and
differentiate, a screening using whole hematopoietic cells
might fail to detect mutations of such a rare population,
thus underestimating the rate of DDX41 mutation among
AML/MDS patients.
DDX41 protein is a DEAD-box type ATP-dependent
RNA helicase [10] in which the helicase domain is highly
conserved. DEAD-box RNA helicases have been shown
to act in many pathways, including pre-mRNA splicing
and ribosome biogenesis. In addition, recent studies pro-
pose roles of RNA helicases, such as RIG-I, in sensing
nucleic acids of microbes incorporated into cells
[16,17]. In addition, some DEAD-box RNA helicases
have multiple functions and have been involved in tumor-
igenesis [18,19]. However, the function of DDX41 has
not been investigated until recently. A recent study re-
ported that DDX41 cooperates with mRNA-splicing
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Figure 4. (continued) (C) Increased binding of RPL5 and RPL11 to MDM2 in p.R525H DDX41-expressing cells. Total protein extracts from K562 cells
expressing DDX41 (WT or p.R525H) or those transfected with an empty vector were subjected to immunoprecipitation analysis using an anti-MDM2 anti-
body or a control IgG, followed by the detection of the RPL5, RPL11, and MDM2 proteins. (D) Expression of RB and its phosphorylated and polyubiquiti-
nated forms of MDM2, Myc-tagged DDX41, actin, and polyubiquitinated proteins in K562 cells transfected with an empty vector or with a DDX41 (WT or
p.R525H) vector. In the immunoprecipitation analysis (right panels indicated as IP), proteins precipitated with an anti-RB antibody were blotted using an
anti–multi-ubiquitin antibody and an anti-RB antibody.
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[1]. However, as we mentioned previously, we identified
a DDX41 p.R525H mutation in AML patients exhibiting
cytopenias in bone marrow and peripheral blood, the
pathogenesis of which has not been known to be con-
nected to mRNA splicing defect. Therefore, we further
investigated the biological functions of DDX41 and its
contribution to the development of AML through an ac-
quired mutation.
The DDX41 localizes at the nuclear matrix and in the
nucleolus, consistent with the putative NLS at the N-termi-
nus. However, contrary to our observation, a recent study
described DDX41 localization in the cytoplasm even
when a full-length cDNA was transfected [6]. The reason
for the discrepancy between our observation and observa-
tions from others is not obvious, but it might be possible
that a short form that we identified for the first time in
this study was mainly expressed in previous studies
describing DDX41 in the cytoplasm. Because it has also
been reported that human DDX41 shuttles between the nu-
cleus and cytoplasm [20], it could be also possible that cells
in which DDX41 is localized mainly in the cytoplasm were
used in previous studies.Although the enforced expression of WT DDX41 in cord
blood–derived cells had minimal effects, substitution of
p.R525 into histidine induced cell cycle arrest, suggesting
that this alteration interferes with cell growth in a
dominant-negative manner. In addition, as expected, the
inhibitory effect of p.R525H DDX41 on cell cycle progres-
sion is due to the loss of ATPase activity. Unexpectedly, the
cell cycle arrest was MDM2-and RB-dependent, but p53-
independent. However, this is consistent with previous
studies arguing that MDM2-dependent but p53-
independent pathways also cause ribosomopathies [21,22].
Our results further indicate an interference of p.R525H
DDX41 in pre-rRNA processing, giving rise to a certain ‘‘ri-
bosomal stress.’’ In humans, the 18S, 5.8S, and 28S rRNA
molecules are transcribed by RNA polymerase I as a single
precursor called 47S pre-rRNA [23], which is then modified
and cleaved post-transcriptionally into mature rRNA
(Supplementary Figure E1B) [24]. The processing of pre-
rRNA occurs mainly in the nucleolus, wherew4,500 puta-
tive nucleolar proteins and small nucleolar RNAs are
thought to participate in this process [25]. Although the mo-
lecular functions of almost none of the nucleolar proteins
have been elucidated (with some exceptions), a recent study
753M. Kadono et al./ Experimental Hematology 2016;44:745–754that performed siRNA-mediated depletion of 625 candidate
nucleolar proteins helped to explain the pre-rRNA process-
ing machinery [9]. Because it has been shown that some
spliceosomal factors, such as hPrp43/DHX15 RNA heli-
case, also participate in pre-rRNA processing [26,27],
DDX41 could play multiple roles. We think that this
pathway can at least partly account for the development
of AML with cytopenias harboring the DDX41 p.R525H
mutation. Hematopoietic stem cells have a low level of pro-
tein synthesis compared with differentiating or growing pro-
genitor cells [28]. Assuming that AML stem cells with the
DDX41 p.R525H mutation are constitutively in a low-
protein synthesis status due to ribosomal stress, the cells
could be able to be maintained under this stress, but they
cannot proliferate or differentiate, which would explain in
part the pathophysiology of a slowly growing AML.
In summary, we propose a mechanism of growth defect
in hematopoietic cells triggered by p.R525H DDX41 occur-
ring in the following order: (1) the p.R525H mutant inhibits
pre-rRNA processing; (2) compromised ribosomal biogen-
esis as a result of impaired rRNA synthesis causes a release
of ribosomal proteins that bind to MDM2; and (3) MDM2-
mediated RB degradation is suppressed, eventually acti-
vating the RB pathway and resulting in the inhibition of
E2F activity. Although this study uncovered a pathogenic
role of p.R525H DDX41 in the slow growth rate of tumor
cells, how the mutation induces AML development and in-
hibits cell differentiation is still not understood. Lethally
irradiated mice transplanted with hematopoietic stem/pro-
genitor cells overexpressing p.R525H DDX41 did not
develop myeloid malignancy, even in the p53-deficient
background (Supplementary Figure E4B, online only, avail-
able at www.exphem.org). Considering the late occurrence
of AML in patients harboring the mutation, age-dependent
epigenetic alterations or other somatic changes may be
required for this mutation to transform hematopoietic cells
fully.
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Supplementary Figure E1. Structure and processing pathways of pre-rRNA. (A) Structure of 47S pre-rRNA. The 50 and 30 ETS and ITS 1 and 2 are spacer
regions that will be removed during pre-rRNA processing, and there are many pre-rRNA intermediates partially retaining these spacers, as shown in (B).
Detailed pre-rRNA cleavage sites and their names are described in a recent review [24]. The regions used for northern probes (ITS1 and ITS2) and amplified
by quantitative PCR analysis (50-01, 01-A0, A0-1, 3-E, E-C, 2-5.8S, and 40-4a) are shown in orange and gray, respectively. (B) Schematic processing path-
ways of pre-rRNA. Three rRNAs (18S, 5.8S, and 28S) are first transcribed as a long polycistronic precursor designated as 47S pre-rRNA. The latter will
subsequently be processed to produce mature rRNAs through pathways, as shown in this schema.
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Supplementary Figure E2. Expression and localization of DDX41 and its short isoform. (A) Endogenous DDX41 expression in four AML cell lines (upper
panels). DDX41 was detected by an antibody against the C-terminus of DDX41. A full-length image of DDX41 immunoblot is shown at right. (B) Exogenous
DDX41 proteins expressed in HEK293 cells. The cells were transfected with a Myc-tagged DDX41 cDNA (cDNA starting from the first and second methi-
onine, designated as p70 and p52, respectively), and the extracts were subjected to immunoblot analysis. Tagging positions are indicated as C (C-terminus) or
N (N-terminus). The C-terminally tagged p70 cDNA also showed the 52-kDa band weakly (lanes 1 and 2), whereas the p70 cDNA tagged at the N-terminus
did not show the 52-kDa band (lane 5 and 6), suggesting that the 52-kDa band is a truncated protein originated from the c-terminal part of DDX41. Indeed,
the p70 cDNA, where the p.M132 (the third methionine) was substituted with an alanine, expressed a very weak 52-kDa band (lane 11), which disappeared
when the p.M127 (the second methionine) was substituted with alanine (lanes 13 and 14). Actin was used as a loading control. A schematic diagram is shown
in the center, and full-length images of DDX41 immunoblot are shown at bottom right. (C) Localization of 52-kDa DDX41 tagged with Myc at its c-terminus.
The experiment was performed as in (A). Scale bars, 20 mm.
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Supplementary Figure E3. Suppression of ribosomal genes in p.R525H DDX41-expressing cord blood cells. (A) Decrease in ribosomal genes (RPLs and
RPSs) in p.R525H DDX41 cord blood cells compared with the cells transfected with WT DDX41-expressing vector. Each bar indicates the ratio of p.R525H
cells to WT cells. (B) GSEA analysis indicating negative enrichment of gene sets related to ribosome biogenesis and positive enrichment of genes upregulated
in RPS14-deficient p.R525H DDX41 cord blood cells. Normalized enrichment score, nominal p value, and FDR q value are shown at the bottom.
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Supplementary Figure E4. There was no growth advantage of p.R525H DDX41-expressing cells in vitro or in vivo. (A) DDX41 (WT or p.R525H)-
expressing THP-1 cell number. THP cells lacking functional p53 were transduced with a DDX41-expressing vector, and viable cells were counted. (B) There
was no growth advantage of p.R525H DDX41-expressing hematopoietic cells in murine BMT experiments. Donor cells (with or without p53þ/ background)
were transduced with an empty/GFP-expressing vector or a DDX41/GFP-expressing vector, followed by transplantation into lethally irradiated recipients.
GFP positivity (%) and peripheral WBC numbers (103/mL) were measured 2–3 months after BMT. No significant difference in GFP signals was observed
between the groups, suggesting that enforced expression of DDX41 pR525H alone does not account for the acquisition of clonogenicity.
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